Markus Abt
About
Markus Abt is a scholar working on Surgery, Oncology and Management Science and Operations Research.
According to data from OpenAlex, Markus Abt has authored 49 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Surgery, 9 papers in Oncology and 8 papers in Management Science and Operations Research. Recurrent topics in Markus Abt's work include Lipoproteins and Cardiovascular Health (8 papers), Optimal Experimental Design Methods (8 papers) and Sperm and Testicular Function (5 papers). Markus Abt is often cited by papers focused on Lipoproteins and Cardiovascular Health (8 papers), Optimal Experimental Design Methods (8 papers) and Sperm and Testicular Function (5 papers). Markus Abt collaborates with scholars based in Switzerland, United States and Germany. Markus Abt's co-authors include David Kallend, Gregory G. Schwartz, Christie M. Ballantyne, Jean‐Claude Tardif, Hardi Mundl, Anders Olsson, Ingar Holme, John J.V. McMurray, Lawrence A. Leiter and Jochen Brumm and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.
In The Last Decade
Markus Abt
49 papers receiving 2.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Markus Abt Switzerland | 19 | 1.5k | 1.1k | 669 | 458 | 376 | 49 | 3.0k | ||
| William Duggan United States | 17 | 1.6k 1.0× | 972 0.9× | 473 0.7× | 394 0.9× | 275 0.7× | 28 | 2.4k | ||
| John A. Farmer United States | 31 | 2.2k 1.4× | 882 0.8× | 1.1k 1.7× | 523 1.1× | 467 1.2× | 105 | 3.8k | ||
| G. Kees Hovingh Netherlands | 30 | 2.1k 1.4× | 1.3k 1.1× | 1.0k 1.5× | 646 1.4× | 394 1.0× | 76 | 3.4k | ||
| Mieke D. Trip Netherlands | 33 | 1.8k 1.2× | 1.0k 0.9× | 1.2k 1.8× | 578 1.3× | 723 1.9× | 70 | 3.6k | ||
| Yuan‐Lin Guo China | 29 | 1.8k 1.2× | 994 0.9× | 1.2k 1.8× | 428 0.9× | 322 0.9× | 156 | 3.2k | ||
| Na‐Qiong Wu China | 31 | 1.9k 1.2× | 1.1k 1.0× | 1.2k 1.8× | 483 1.1× | 342 0.9× | 192 | 3.3k | ||
| Cheng‐Gang Zhu China | 31 | 2.0k 1.3× | 1.2k 1.0× | 1.5k 2.2× | 423 0.9× | 303 0.8× | 209 | 3.7k | ||
| Rui‐Xia Xu China | 33 | 1.7k 1.1× | 714 0.6× | 1.0k 1.5× | 630 1.4× | 785 2.1× | 158 | 3.5k | ||
| Kouji Kajinami Japan | 27 | 1.4k 0.9× | 424 0.4× | 498 0.7× | 462 1.0× | 336 0.9× | 82 | 2.3k | ||
| Michel Komajda France | 13 | 1.7k 1.1× | 1.7k 1.5× | 1.0k 1.6× | 459 1.0× | 830 2.2× | 25 | 3.5k |
Countries citing papers authored by Markus Abt
Since
Specialization
Citations
This map shows the geographic impact of Markus Abt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Abt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Abt more than expected).
Fields of papers citing papers by Markus Abt
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Markus Abt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Abt. The network helps show where Markus Abt may publish in the future.
Co-authorship network of co-authors of Markus Abt
This figure shows the co-authorship network connecting the top 25 collaborators of Markus Abt. A scholar is included among the top collaborators of Markus Abt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Abt. Markus Abt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Burger, Hans Ulrich, Tom Van de Casteele, Khadija Rantell, et al.. (2023). Opportunities and challenges with decentralized trials in Neuroscience. Biometrical Journal. 65(8). e2200370–e2200370.
2.
Umbricht, Daniel, Markus Abt, Christopher H. Chatham, et al.. (2021). Proof-of-Mechanism Study of the Phosphodiesterase 10 Inhibitor RG7203 in Patients With Schizophrenia and Negative Symptoms. SHILAP Revista de lepidopterología. 1(1). 70–77.
3.
Hantel, Stefan, B. Nhi Beasley, Lee‐Jen Wei, et al.. (2019). Restricted mean survival time for the analysis of cardiovascular outcome trials assessing non-inferiority: Case studies from antihyperglycemic drug development. American Heart Journal. 215. 178–186.
4.
Abt, Markus, et al.. (2019). A Framework Proposal to Follow‐Up on Preclinical Convulsive Signals of a New Molecular Entity in First‐in‐Human Studies Using Electroencephalographic Monitoring. Clinical Pharmacology & Therapeutics. 106(5). 968–980.
5.
Umbricht, Daniel, Juergen Dukart, Markus Abt, et al.. (2018). S43. A PROOF-OF-MECHANISM STUDY OF THE PDE10 INHIBITOR RG7203 IN PATIENTS WITH PROBING REWARD FUNCTIONS WITH IMAGING AND BEHAVIORAL APPROACHES. Schizophrenia Bulletin. 44(suppl_1). S340–S341.
6.
Morcos, Peter N., Katrijn Bogman, Stanislas Hubeaux, et al.. (2017). Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies. Cancer Chemotherapy and Pharmacology. 79(3). 559–568.
7.
Joshi, Francis R., Markus Abt, Mark Woodward, et al.. (2016). Does Vascular Calcification Accelerate Inflammation?. Journal of the American College of Cardiology. 67(1). 69–78.
8.
Rufibach, Kaspar, Hans Ulrich Burger, & Markus Abt. (2016). Bayesian predictive power: choice of prior and some recommendations for its use as probability of success in drug development. Pharmaceutical Statistics. 15(5). 438–446.
9.
Schwartz, Gregory G., Markus Abt, Weihang Bao, et al.. (2015). Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins. Journal of the American College of Cardiology. 65(21). 2267–2275.
10.
Abt, Markus, et al.. (2015). Subcutaneous Bioavailability of Taspoglutide at 3 Different Injection Sites in Healthy Overweight/Obese Subjects. Clinical Therapeutics. 37(11). 2439–2448.
11.
Rufibach, Kaspar, Paul Jordan, & Markus Abt. (2014). Sequentially updating the likelihood of success of a Phase 3 pivotal time-to-event trial based on interim analyses or external information. Journal of Biopharmaceutical Statistics. 26(2). 191–201.
12.
Zhi, Jianguo, Eric X. Chen, Pierre Major, et al.. (2011). A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology. 68(5). 1199–1206.
13.
Derks, Michael, et al.. (2010). No clinically relevant drug–drug interactions when dalcetrapib is co-administered with atorvastatin. Expert Opinion on Investigational Drugs. 19(10). 1135–1145.
14.
Derks, Michael, Markus Abt, & Mary C. Phelan. (2010). Lack of clinically relevant drug–drug interactions when dalcetrapib is co‐administered with ezetimibe. British Journal of Clinical Pharmacology. 70(6). 825–833.
15.
Derks, Michael, et al.. (2010). Coadministration of Dalcetrapib With Pravastatin, Rosuvastatin, or Simvastatin: No Clinically Relevant Drug‐Drug Interactions. The Journal of Clinical Pharmacology. 50(10). 1188–1201.
16.
Derks, Michael, et al.. (2010). Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing. European Journal of Clinical Pharmacology. 66(8). 775–783.
17.
Sterzik, K., Markus Abt, Dieter Grab, Volker Schneider, & Erwin Strehler. (2000). Predicting the histologic dating of an endometrial biopsy specimen with the use of doppler ultrasonography and hormone measurements in patients undergoing spontaneous ovulatory cycles. Fertility and Sterility. 73(1). 94–98.
18.
Strehler, Erwin, K. Sterzik, M. De Santo, et al.. (1997). The Effect of Follicle‐Stimulating Hormone Therapy on Sperm Quality: An Ultrastructural Mathematical Evaluation. Journal of Andrology. 18(4). 439–447.
19.
Sterzik, K., Erwin Strehler, M. De Santo, et al.. (1996). Influence of smoking on fertility in women attending an in vitro fertilization program. Fertility and Sterility. 65(4). 810–814.
20.
Sterzik, K., Erwin Strehler, Markus Abt, & B. Rosenbusch. (1994). In Vitro Kallikrein Treatment of Human Spermatozoa: Stimulation of Sperm Penetration into Zona-Free Hamster Eggs Depends on the Quality of Initial Semen Parameters but not on Constituents of the Kallikrein-Kinin System in Seminal Plasma. The Journal of Urology. 151(6). 1712–1714.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by William Duggan Breakdown of academic impact, for papers by John A. Farmer Breakdown of academic impact, for papers by G. Kees Hovingh Breakdown of academic impact, for papers by Mieke D. Trip Breakdown of academic impact, for papers by Yuan‐Lin Guo Breakdown of academic impact, for papers by Na‐Qiong Wu Breakdown of academic impact, for papers by Cheng‐Gang Zhu Breakdown of academic impact, for papers by Rui‐Xia Xu Breakdown of academic impact, for papers by Kouji Kajinami Breakdown of academic impact, for papers by Michel Komajda